Albendazole Is Rapidly Converted In The Liver To The Primary Metabolite

Albendazole sulfoxide is 70% bound to plasma protein and is widely distributed throughout

the body; it has been detected in urine, bile, liver, cyst wall, cyst fluid, and cerebral spinal fluid (CSF). Concentrations in plasma were 3- to 10-fold and 2- to 4-fold higher than those simultaneously determined in cyst fluid and CSF, respectively. Limited in vitro and clinical data suggest that albendazole sulfoxide may be eliminated from cysts at a slower rate than observed in plasma.

Albendazole is rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine. Following oral administration, albendazole has not been detected in human urine. Urinary excretion of albendazole sulfoxide is a minor elimination pathway with less than 1% of the dose recovered in the urine. Biliary elimination presumably accounts for a portion of the elimination as evidenced by biliary concentrations of albendazole sulfoxide similar to those achieved in plasma.

The pharmacokinetics of albendazole suppliers in patients with impaired renal function have not been studied. However, since renal elimination of albendazole and its primary metabolite, albendazole sulfoxide, is negligible, it is unlikely that clearance of these compounds would be altered in these patients.In patients with evidence of extrahepatic obstruction (n = 5), the systemic availability of albendazole sulfoxide was increased, as indicated by a 2-fold increase in maximum serum concentration and a 7-fold increase in area under the curve. The rate of absorption/conversion and elimination of albendazole sulfoxide appeared to be prolonged with mean Tmax and serum elimination half-life values of 10 hours and 31.7 hours, respectively. Plasma concentrations of parent albendazole tablets were measurable in only 1 of 5 patients.

Following single-dose administration of 200 mg to 300 mg (approximately 10 mg/kg) albendazole to 3 fasted and 2 fed pediatric patients with hydatid cyst disease (age range 6 to 13 years), albendazole sulfoxide pharmacokinetics were similar to those observed in fed adults.Although no studies have investigated the effect of age on albendazole sulfoxide pharmacokinetics, data in 26 hydatid cyst patients (up to 79 years) suggest pharmacokinetics similar to those in young healthy subjects.The principal mode of action for albendazole manufacturer is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.

source:pharmaceutical-generic.blogtownhall

by: wenjun

POST COMMENT

Are You Confident You Can Deliver On Your Client Value Proposition? Anxiety Disorder Treatments Can be Effective for Social Phobias Anxiety Disorder Treatments Mold Allergies Treatments Get A Hollywood Smile With Teeth Whitening Treatments Plaque Psoriasis Treatment Guidelines Prevention Notes - Important Part Of Treatment Process For Cellulitis Infection Tim Lincecum, Edgar Renteria deliver Giants' first title since 1954 Info On Colon Cleansing That Prevents Cancer Arthritis Treatment Breast Cancer Insight, A Full Resource To Help Identify Signs Of Breast Cancer Hypnosis for Anxiety Treatment The Search To Find The Best Treatment For Anorexia